Smart rings and smartwatches are providing consumers with reams of health information. Clinical device makers like DexCom needn’t worry. Read More...
Cassava Sciences Adviser Indicted on Fraud Charges
A key adviser to Alzheimer’s drug developer Cassava Sciences was indicted by a federal grand jury this week for allegedly submitting fabricated and falsified scientific data to obtain $16 million in grants from the National Institutes of Health. Hoau-Yan Wang, a medical professor at the CUNY School of Medicine at the City College of New York, co-wrote multiple journal articles with Cassava that supported the scientific rationale for its drug Simufilam, which is currently in late-stage testing in Alzheimer’s disease.
The Wall Street Journal•
Add Comment